Skip to main content

Table 1 Characteristics of trials

From: The effect of catheter-based sham renal denervation in hypertension: systematic review and meta-analysis

First Author/Trial

Year

Total Patients (Sham)

Follow-Up Duration (Months)

Type of Sham

Investigational Device

Primary Efficacy Outcome

Participating Centers

Enrolment Period

Trial Design

SYMPLICITY HTN-3

2014

171

6

Renal Angiography

Symplicity Renal Denervation System (Medtronic)

Mean change in office systolic blood pressure from baseline to 6 months

88 sites in the United States

October 2011 to May 2013

Prospective, single-blind, randomized, sham-controlled trial

Desch et al.

2015

36†/35‡

6

Renal Angiography

Symplicity Flex Cathether (by Ardian Inc, Palo Alto, CA, USA)

Change in 24-hour systolic blood pressure at 6 months

Single-center, Leipzig, Germany

July 2012 to January 2014

Sham-controlled, randomized, single-center trial

ReSet

2016

33†/32‡

3

Radiograph scan while the patient was sedated

Symplicity

Renal Denervation Catheter (Medtronic)

Mean change in daytime systolic ambulatory blood pressure measurements from baseline to 3 months

Single-center, Skejby, Denmark

No information

Sham-controlled, double-blind, randomized single-center trial

RADIANCE-HTN SOLO

2018

72

2

Renal Angiography

Paradise

endovascular ultrasound renal denervation system

Mean change in daytime ambulatory systolic blood pressure from baseline to 2 months

21 centers in the USA and 18 in Europe

March 28, 2016 to December 28, 2017

Multicenter, single-blind, randomized, sham-controlled trial

SPYRAL HTN-OFF MED Pivotal

2020

165†/ 137*/130**

3

Renal Angiography

Symplicity Spyral multielectrode renal denervation catheter# and Symplicity G3 radiofrequency Generator$

Change in mean 24-h systolic blood pressure from baseline to 3 months

44 centers in Australia, Austria, Canada, Germany, Greece, Ireland, United Kingdom and United States of America

June 25, 2015 to October 15, 2019

Prospective, single-blinded, sham-control trial

SPYRAL HTN-ON MED

2018

42† / 39‡

6

Renal Angiography

Symplicity Spyral multielectrode renal denervation catheter# and Symplicity G3 radiofrequency generator$

Change in ambulatory blood pressure from baseline to 6 months

25 centers in the USA, Germany, Japan, UK, Australia, Austria and Greece

July 22, 2015 to June 14, 2017

Randomized, Single-blind, sham-control, proof-of-concept trial

REDUCE HTN: REINFORCE

2020

17*/15**

2

(8 weeks)

Renal Angiography

Vessix Renal Denervation system

Mean reduction in average 24-h ambulatory systolic blood pressure by 8 weeks post-randomization

12 centers in the United States

April 2015 to October 2017

Prospective, multicenter, single blinded, randomized, controlled, pilot trial

REQUIRE

2021

71†/ 66*/67**

3

Renal Angiography

Paradise

endovascular ultrasound renal denervation system

Change in 24-hour ambulatory systolic blood pressure from baseline to 3 months

53 centers in Japan and Korea

January 12, 2017 to March 31, 2020

Multicenter, single-blind, randomized, sham-controlled trial

RADIANCE-HTN TRIO

2021

67

2

Renal Angiography

Paradise

endovascular ultrasound renal denervation system

Change in daytime ambulatory systolic blood pressure from baseline to 2 months

28 centers in Europe and 28 centers in USA

March 11, 2016 to March 13, 2020

Multicenter, single-blind, randomized, sham-controlled trial

  1. † Randomized patients; ‡ Patients included in iTT analysis for both the outcomes “change in office blood pressure” and “change in 24 h ambulatory blood pressure”; * Patients included in iTT analysis for the outcome “change in office blood pressure”; ** Patients included in iTT analysis for the outcome “change in 24 h ambulatory blood pressure.”; # Medtronic; Galway, Ireland); $ (Medtronic; Minneapolis, MN, USA)